All In Biotech

Drug Trial Radar · NCT04416126

Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

A Phase 1 Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jun 1, 2020

Primary completion

Dec 9, 2020

Study completion Dec 9, 2020

Sponsor

Lead sponsor
Arcturus Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-810 in healthy adult subjects.

Conditions

  • Ornithine Transcarbamylase Deficiency

Interventions

  • ARCT-810Biological

    ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.

  • PlaceboOther

    The placebo for this study is 0.9% sterile saline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and dose-relationship of AEsTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Auckland Clinical Studies (ACS) Ltd.

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.